nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.449	1	CbGbCtD
Ondansetron—Stridor—Riluzole—amyotrophic lateral sclerosis	0.0262	0.0752	CcSEcCtD
Ondansetron—HTR3A—cranial nerve—amyotrophic lateral sclerosis	0.019	0.111	CbGeAlD
Ondansetron—HTR1B—cranial nerve—amyotrophic lateral sclerosis	0.016	0.0927	CbGeAlD
Ondansetron—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0156	0.0448	CcSEcCtD
Ondansetron—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.0134	0.0386	CcSEcCtD
Ondansetron—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.013	0.0374	CcSEcCtD
Ondansetron—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0305	CcSEcCtD
Ondansetron—HTR3A—nerve—amyotrophic lateral sclerosis	0.00975	0.0566	CbGeAlD
Ondansetron—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00944	0.0271	CcSEcCtD
Ondansetron—OPRM1—nerve—amyotrophic lateral sclerosis	0.00894	0.0519	CbGeAlD
Ondansetron—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00853	0.0245	CcSEcCtD
Ondansetron—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00853	0.0245	CcSEcCtD
Ondansetron—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00848	0.0244	CcSEcCtD
Ondansetron—SLC47A1—hindbrain—amyotrophic lateral sclerosis	0.00717	0.0417	CbGeAlD
Ondansetron—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00653	0.0188	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00639	0.0184	CcSEcCtD
Ondansetron—HTR4—brain—amyotrophic lateral sclerosis	0.00621	0.0361	CbGeAlD
Ondansetron—SLC47A2—nervous system—amyotrophic lateral sclerosis	0.00615	0.0358	CbGeAlD
Ondansetron—SLC47A2—central nervous system—amyotrophic lateral sclerosis	0.00593	0.0344	CbGeAlD
Ondansetron—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00588	0.0169	CcSEcCtD
Ondansetron—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00571	0.0164	CcSEcCtD
Ondansetron—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00563	0.0162	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00557	0.016	CcSEcCtD
Ondansetron—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00535	0.0154	CcSEcCtD
Ondansetron—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00521	0.015	CcSEcCtD
Ondansetron—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.005	0.0144	CcSEcCtD
Ondansetron—HTR1A—hindbrain—amyotrophic lateral sclerosis	0.00494	0.0287	CbGeAlD
Ondansetron—SLC47A2—brain—amyotrophic lateral sclerosis	0.0047	0.0273	CbGeAlD
Ondansetron—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.0047	0.0135	CcSEcCtD
Ondansetron—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00468	0.0134	CcSEcCtD
Ondansetron—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00464	0.0133	CcSEcCtD
Ondansetron—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00451	0.013	CcSEcCtD
Ondansetron—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00436	0.0125	CcSEcCtD
Ondansetron—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.0043	0.0124	CcSEcCtD
Ondansetron—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00428	0.0123	CcSEcCtD
Ondansetron—HTR3A—brainstem—amyotrophic lateral sclerosis	0.00419	0.0243	CbGeAlD
Ondansetron—SLC47A1—brainstem—amyotrophic lateral sclerosis	0.00411	0.0239	CbGeAlD
Ondansetron—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00405	0.0116	CcSEcCtD
Ondansetron—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.004	0.0115	CcSEcCtD
Ondansetron—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00397	0.0114	CcSEcCtD
Ondansetron—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00388	0.0112	CcSEcCtD
Ondansetron—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00387	0.0111	CcSEcCtD
Ondansetron—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00386	0.0111	CcSEcCtD
Ondansetron—Chills—Riluzole—amyotrophic lateral sclerosis	0.00384	0.011	CcSEcCtD
Ondansetron—OPRM1—brainstem—amyotrophic lateral sclerosis	0.00384	0.0223	CbGeAlD
Ondansetron—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00382	0.011	CcSEcCtD
Ondansetron—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00367	0.0106	CcSEcCtD
Ondansetron—HTR1B—brainstem—amyotrophic lateral sclerosis	0.00351	0.0204	CbGeAlD
Ondansetron—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00349	0.01	CcSEcCtD
Ondansetron—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00346	0.00994	CcSEcCtD
Ondansetron—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00343	0.00985	CcSEcCtD
Ondansetron—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00341	0.00979	CcSEcCtD
Ondansetron—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00967	CcSEcCtD
Ondansetron—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00334	0.00961	CcSEcCtD
Ondansetron—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00947	CcSEcCtD
Ondansetron—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00328	0.00942	CcSEcCtD
Ondansetron—Cough—Riluzole—amyotrophic lateral sclerosis	0.00325	0.00935	CcSEcCtD
Ondansetron—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00929	CcSEcCtD
Ondansetron—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00912	CcSEcCtD
Ondansetron—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00909	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00315	0.00906	CcSEcCtD
Ondansetron—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00902	CcSEcCtD
Ondansetron—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00892	CcSEcCtD
Ondansetron—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00304	0.00875	CcSEcCtD
Ondansetron—Shock—Riluzole—amyotrophic lateral sclerosis	0.00299	0.00861	CcSEcCtD
Ondansetron—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00298	0.00858	CcSEcCtD
Ondansetron—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00297	0.00854	CcSEcCtD
Ondansetron—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00295	0.0085	CcSEcCtD
Ondansetron—SLC47A1—medulla oblongata—amyotrophic lateral sclerosis	0.00287	0.0167	CbGeAlD
Ondansetron—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00817	CcSEcCtD
Ondansetron—HTR1A—brainstem—amyotrophic lateral sclerosis	0.00283	0.0165	CbGeAlD
Ondansetron—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00785	CcSEcCtD
Ondansetron—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0078	CcSEcCtD
Ondansetron—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00778	CcSEcCtD
Ondansetron—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00268	0.0156	CbGeAlD
Ondansetron—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00755	CcSEcCtD
Ondansetron—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00754	CcSEcCtD
Ondansetron—Pain—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00748	CcSEcCtD
Ondansetron—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00748	CcSEcCtD
Ondansetron—SLC47A1—spinal cord—amyotrophic lateral sclerosis	0.00256	0.0149	CbGeAlD
Ondansetron—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00721	CcSEcCtD
Ondansetron—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00715	CcSEcCtD
Ondansetron—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00695	CcSEcCtD
Ondansetron—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00691	CcSEcCtD
Ondansetron—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00691	CcSEcCtD
Ondansetron—OPRM1—spinal cord—amyotrophic lateral sclerosis	0.00239	0.0139	CbGeAlD
Ondansetron—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00644	CcSEcCtD
Ondansetron—HTR3A—nervous system—amyotrophic lateral sclerosis	0.00219	0.0127	CbGeAlD
Ondansetron—HTR1B—spinal cord—amyotrophic lateral sclerosis	0.00218	0.0127	CbGeAlD
Ondansetron—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00628	CcSEcCtD
Ondansetron—SLC47A1—nervous system—amyotrophic lateral sclerosis	0.00215	0.0125	CbGeAlD
Ondansetron—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00619	CcSEcCtD
Ondansetron—HTR3A—central nervous system—amyotrophic lateral sclerosis	0.00211	0.0123	CbGeAlD
Ondansetron—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00598	CcSEcCtD
Ondansetron—SLC47A1—central nervous system—amyotrophic lateral sclerosis	0.00207	0.012	CbGeAlD
Ondansetron—SLC47A1—cerebellum—amyotrophic lateral sclerosis	0.00203	0.0118	CbGeAlD
Ondansetron—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00578	CcSEcCtD
Ondansetron—OPRM1—nervous system—amyotrophic lateral sclerosis	0.00201	0.0117	CbGeAlD
Ondansetron—OPRM1—central nervous system—amyotrophic lateral sclerosis	0.00194	0.0112	CbGeAlD
Ondansetron—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00556	CcSEcCtD
Ondansetron—Rash—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00552	CcSEcCtD
Ondansetron—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00192	0.00551	CcSEcCtD
Ondansetron—Headache—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00548	CcSEcCtD
Ondansetron—HTR1B—nervous system—amyotrophic lateral sclerosis	0.00184	0.0107	CbGeAlD
Ondansetron—HTR1B—central nervous system—amyotrophic lateral sclerosis	0.00177	0.0103	CbGeAlD
Ondansetron—HTR1A—spinal cord—amyotrophic lateral sclerosis	0.00176	0.0102	CbGeAlD
Ondansetron—KCNH2—medulla oblongata—amyotrophic lateral sclerosis	0.00176	0.0102	CbGeAlD
Ondansetron—HTR3A—brain—amyotrophic lateral sclerosis	0.00168	0.00974	CbGeAlD
Ondansetron—SLC47A1—brain—amyotrophic lateral sclerosis	0.00165	0.00957	CbGeAlD
Ondansetron—KCNH2—spinal cord—amyotrophic lateral sclerosis	0.00157	0.00911	CbGeAlD
Ondansetron—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00154	0.00894	CbGeAlD
Ondansetron—OPRM1—brain—amyotrophic lateral sclerosis	0.00154	0.00893	CbGeAlD
Ondansetron—HTR1A—nervous system—amyotrophic lateral sclerosis	0.00148	0.00863	CbGeAlD
Ondansetron—HTR1A—central nervous system—amyotrophic lateral sclerosis	0.00143	0.0083	CbGeAlD
Ondansetron—HTR1B—brain—amyotrophic lateral sclerosis	0.00141	0.00817	CbGeAlD
Ondansetron—HTR1A—cerebellum—amyotrophic lateral sclerosis	0.0014	0.00812	CbGeAlD
Ondansetron—CYP2E1—medulla oblongata—amyotrophic lateral sclerosis	0.00135	0.00787	CbGeAlD
Ondansetron—KCNH2—nervous system—amyotrophic lateral sclerosis	0.00132	0.00768	CbGeAlD
Ondansetron—KCNH2—central nervous system—amyotrophic lateral sclerosis	0.00127	0.00739	CbGeAlD
Ondansetron—KCNH2—cerebellum—amyotrophic lateral sclerosis	0.00124	0.00723	CbGeAlD
Ondansetron—CYP2E1—spinal cord—amyotrophic lateral sclerosis	0.00121	0.00702	CbGeAlD
Ondansetron—HTR1A—brain—amyotrophic lateral sclerosis	0.00113	0.00659	CbGeAlD
Ondansetron—CYP2E1—nervous system—amyotrophic lateral sclerosis	0.00102	0.00591	CbGeAlD
Ondansetron—KCNH2—brain—amyotrophic lateral sclerosis	0.00101	0.00587	CbGeAlD
Ondansetron—CYP2E1—central nervous system—amyotrophic lateral sclerosis	0.00098	0.00569	CbGeAlD
Ondansetron—CYP2E1—cerebellum—amyotrophic lateral sclerosis	0.000958	0.00557	CbGeAlD
Ondansetron—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000819	0.00476	CbGeAlD
Ondansetron—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000806	0.00468	CbGeAlD
Ondansetron—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000789	0.00458	CbGeAlD
Ondansetron—CYP2E1—brain—amyotrophic lateral sclerosis	0.000778	0.00452	CbGeAlD
Ondansetron—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000776	0.00451	CbGeAlD
Ondansetron—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000758	0.00441	CbGeAlD
Ondansetron—CYP2D6—brain—amyotrophic lateral sclerosis	0.000616	0.00358	CbGeAlD
Ondansetron—HTR4—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000119	0.00386	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000117	0.0038	CbGpPWpGaD
Ondansetron—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000114	0.00371	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000112	0.00364	CbGpPWpGaD
Ondansetron—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000105	0.00342	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000101	0.00328	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.0001	0.00326	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	9.67e-05	0.00314	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	9.67e-05	0.00314	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	9.6e-05	0.00312	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	9.52e-05	0.00309	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.25e-05	0.00301	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.99e-05	0.00292	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	8.73e-05	0.00284	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.7e-05	0.00283	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	8.53e-05	0.00277	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	8.51e-05	0.00277	CbGpPWpGaD
Ondansetron—CYP3A7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.36e-05	0.00272	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.25e-05	0.00268	CbGpPWpGaD
Ondansetron—CYP3A7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.24e-05	0.00268	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	8.13e-05	0.00264	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.99e-05	0.0026	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	7.36e-05	0.00239	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	7.33e-05	0.00238	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	7.29e-05	0.00237	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.09e-05	0.0023	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.01e-05	0.00228	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	6.97e-05	0.00226	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	6.95e-05	0.00226	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	6.7e-05	0.00218	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TPK1—amyotrophic lateral sclerosis	6.41e-05	0.00208	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—VAPB—amyotrophic lateral sclerosis	6.41e-05	0.00208	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	6.28e-05	0.00204	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	6.26e-05	0.00203	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.23e-05	0.00202	CbGpPWpGaD
Ondansetron—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	6.22e-05	0.00202	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	6.15e-05	0.002	CbGpPWpGaD
Ondansetron—CYP2E1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.05e-05	0.00197	CbGpPWpGaD
Ondansetron—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.04e-05	0.00196	CbGpPWpGaD
Ondansetron—CYP2E1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.97e-05	0.00194	CbGpPWpGaD
Ondansetron—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.96e-05	0.00194	CbGpPWpGaD
Ondansetron—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	5.93e-05	0.00193	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	5.9e-05	0.00192	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.86e-05	0.00191	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.86e-05	0.0019	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—VAPA—amyotrophic lateral sclerosis	5.86e-05	0.0019	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	5.73e-05	0.00186	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.71e-05	0.00185	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	5.54e-05	0.0018	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	5.46e-05	0.00177	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.45e-05	0.00177	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	5.42e-05	0.00176	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	5.33e-05	0.00173	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	5.31e-05	0.00172	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.18e-05	0.00168	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—FIG4—amyotrophic lateral sclerosis	5.12e-05	0.00166	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	5.07e-05	0.00165	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.01e-05	0.00163	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.96e-05	0.00161	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.89e-05	0.00159	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.82e-05	0.00157	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.82e-05	0.00157	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.64e-05	0.00151	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.64e-05	0.00151	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—DAO—amyotrophic lateral sclerosis	4.63e-05	0.0015	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	4.63e-05	0.0015	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	4.63e-05	0.0015	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.52e-05	0.00147	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.38e-05	0.00142	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	4.36e-05	0.00142	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.3e-05	0.0014	CbGpPWpGaD
Ondansetron—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.3e-05	0.0014	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	4.27e-05	0.00139	CbGpPWpGaD
Ondansetron—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.26e-05	0.00138	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.24e-05	0.00138	CbGpPWpGaD
Ondansetron—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.24e-05	0.00138	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	4.23e-05	0.00138	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.22e-05	0.00137	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—C3—amyotrophic lateral sclerosis	4.22e-05	0.00137	CbGpPWpGaD
Ondansetron—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.2e-05	0.00136	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.16e-05	0.00135	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.02e-05	0.0013	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.95e-05	0.00128	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.94e-05	0.00128	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.87e-05	0.00126	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.78e-05	0.00123	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.72e-05	0.00121	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.71e-05	0.00121	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	3.7e-05	0.0012	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	3.7e-05	0.0012	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.68e-05	0.0012	CbGpPWpGaD
Ondansetron—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.64e-05	0.00118	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.64e-05	0.00118	CbGpPWpGaD
Ondansetron—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.59e-05	0.00117	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	3.51e-05	0.00114	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.46e-05	0.00113	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.45e-05	0.00112	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.43e-05	0.00111	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.41e-05	0.00111	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—DAO—amyotrophic lateral sclerosis	3.35e-05	0.00109	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	3.35e-05	0.00109	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.34e-05	0.00108	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.29e-05	0.00107	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.29e-05	0.00107	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	3.26e-05	0.00106	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	3.26e-05	0.00106	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	3.24e-05	0.00105	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.21e-05	0.00104	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.21e-05	0.00104	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.06e-05	0.000995	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.04e-05	0.000989	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.04e-05	0.000988	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.01e-05	0.000978	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	2.99e-05	0.00097	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.96e-05	0.000963	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.95e-05	0.000957	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.95e-05	0.000957	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.93e-05	0.000952	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.85e-05	0.000926	CbGpPWpGaD
Ondansetron—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.81e-05	0.000913	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.8e-05	0.00091	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.79e-05	0.000906	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.79e-05	0.000906	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.78e-05	0.000902	CbGpPWpGaD
Ondansetron—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.77e-05	0.0009	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.77e-05	0.0009	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	2.66e-05	0.000864	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.63e-05	0.000855	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.63e-05	0.000853	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.62e-05	0.00085	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	2.61e-05	0.000848	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.6e-05	0.000845	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.59e-05	0.00084	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.55e-05	0.000829	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.54e-05	0.000826	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.54e-05	0.000826	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.54e-05	0.000824	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.45e-05	0.000796	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.38e-05	0.000775	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.38e-05	0.000773	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.37e-05	0.000771	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.36e-05	0.000767	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.35e-05	0.000765	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSR—amyotrophic lateral sclerosis	2.35e-05	0.000762	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.34e-05	0.000761	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.26e-05	0.000733	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.23e-05	0.000725	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.23e-05	0.000725	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.17e-05	0.000703	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.16e-05	0.000702	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.15e-05	0.000699	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.15e-05	0.000699	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.1e-05	0.000684	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.02e-05	0.000655	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.01e-05	0.000654	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.97e-05	0.00064	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.93e-05	0.000626	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.92e-05	0.000625	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.91e-05	0.000621	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.89e-05	0.000614	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.87e-05	0.000606	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.83e-05	0.000595	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.82e-05	0.00059	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.81e-05	0.000589	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.8e-05	0.000586	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.8e-05	0.000584	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.79e-05	0.000581	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.78e-05	0.000577	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.72e-05	0.000559	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.71e-05	0.000557	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.67e-05	0.000541	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.66e-05	0.000541	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.65e-05	0.000536	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.65e-05	0.000536	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.59e-05	0.000516	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.56e-05	0.000506	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.54e-05	0.0005	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.54e-05	0.0005	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.53e-05	0.000498	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.53e-05	0.000497	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.5e-05	0.000488	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.00047	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.44e-05	0.000467	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.43e-05	0.000464	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.41e-05	0.000458	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.37e-05	0.000445	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.37e-05	0.000444	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.36e-05	0.000441	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.36e-05	0.00044	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.31e-05	0.000427	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	0.000417	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.28e-05	0.000416	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.28e-05	0.000415	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.24e-05	0.000402	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.19e-05	0.000387	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.18e-05	0.000383	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.17e-05	0.000381	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.16e-05	0.000378	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.16e-05	0.000376	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.13e-05	0.000367	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.1e-05	0.000358	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.09e-05	0.000354	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	1.08e-05	0.000351	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.06e-05	0.000343	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.05e-05	0.000341	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.04e-05	0.000336	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.03e-05	0.000336	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.84e-06	0.00032	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.74e-06	0.000317	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.52e-06	0.000309	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.5e-06	0.000309	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.07e-06	0.000295	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	8.94e-06	0.00029	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.68e-06	0.000282	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.47e-06	0.000275	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—APOE—amyotrophic lateral sclerosis	7.83e-06	0.000254	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	7.81e-06	0.000254	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.57e-06	0.000246	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.49e-06	0.000244	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.41e-06	0.000241	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.35e-06	0.000239	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.28e-06	0.000237	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.24e-06	0.000235	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.16e-06	0.000233	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.75e-06	0.000219	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.69e-06	0.000218	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.68e-06	0.000217	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.43e-06	0.000209	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.32e-06	0.000205	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.22e-06	0.000202	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.77e-06	0.000187	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.72e-06	0.000186	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.67e-06	0.000184	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.56e-06	0.000181	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	5.51e-06	0.000179	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.45e-06	0.000177	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.36e-06	0.000174	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.35e-06	0.000174	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.9e-06	0.000159	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.86e-06	0.000158	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.8e-06	0.000156	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	4.71e-06	0.000153	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.41e-06	0.000143	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.29e-06	0.000139	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.81e-06	0.000124	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.77e-06	0.000123	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.7e-06	0.00012	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.63e-06	0.000118	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.22e-06	0.000105	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.49e-06	8.09e-05	CbGpPWpGaD
